Nanocrystalline Megestrol Acetate Suspension
Nutritional Deficiency Disease
Explore 4 assets in Nutritional Deficiency Disease →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07565415CT.gov Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nutritional Deficiency Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nanocrystalline Megestrol Acetate Suspension (this asset) | Nanfang Hospital, Southern Medical University | P2 | CCC · 53 |
| Retrovir | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | P4 | BB |
| Methoxy Polyethylene Glycol-Epoetin Beta | Taipei Veterans General Hospital, Taiwan | P4 | BB |
| Intralipid | Johane Allard | P4 | BB |
| Guanfacine | Maimonides Medical Center | P4 | BB |
| Lamivudine | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | P4 | BB |
| Thalidomide | Chinese University of Hong Kong | P4 | BB |
| Clinoleic | Johane Allard | P4 | BB |
| Mirtazapine | Montefiore Medical Center | P4 | BB |
+23 more in the Nutritional Deficiency Disease cohort
Other indications for Nanocrystalline Megestrol Acetate Suspension
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | B · 56 |
| Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- RetrovirInternational Maternal Pediatric Adolescent AIDS Clinical Trials GroupBB
- Methoxy Polyethylene Glycol-Epoetin BetaTaipei Veterans General Hospital, TaiwanBB
- IntralipidJohane AllardBB
- GuanfacineMaimonides Medical CenterBB
- LamivudineInternational Maternal Pediatric Adolescent AIDS Clinical Trials GroupBB
Citation
Floatz Terminal. Nanocrystalline Megestrol Acetate Suspension in Nutritional Deficiency Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nanocrystalline-megestrol-acetate-suspension-nutritional-deficiency-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →